First TB Drug In 40 Years Spurs Warnings Of India's Antibiotics Excesses
This article was originally published in PharmAsia News
The first new tuberculosis drug in 40 years, by a Johnson & Johnson subsidiary, is considered likely to face a tough approval process in India because of the greater threat it could be over-used, leading more quickly to resistant forms of the bacteria.
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.